EPS exceeded forecasts by 15.38%, reflecting effective cost management. Revenue missed expectations by 60.26%, raising concerns about growth prospects. The stock price fell by 5.34% in pre-market ...

Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...

Recursion Pharmaceuticals Inc. reported its first-quarter earnings for 2026, revealing a mixed financial picture. The company posted an earnings per share (EPS) of -0.22, surpassing analyst ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...

Anthropic’s Project Glasswing, an industry-wide initiative built around the restricted-access Claude Mythos Preview model, is ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...